MAP3K3 and MAP3K14 are in the MAPK/ERK pathway which is a target of many novel therapeutic agents [53], and SRC is a well known oncogene and a candidate target in lung cancer [54]. This evidence concerns the gene MAP3K3 and lung carcinoma.